The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associatedautologous anti-vimentin antibody, CLN-IgG (Pritumumab)”. Click here to download the paper. Click here to download the supplementary information.
This author has yet to write their bio.Meanwhile lets just say that we are proud Nascent contributed a whooping 28 entries.
Entries by Nascent
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman. Click this link to download a PDF detailing the conference details, and how to register.
The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy: The greatest excitement is reserved for immunotherapy, a new approach that has emerged in the past few years. The human immune system is equipped with a set of brakes that cancer cells are able to activate; the first immunotherapy treatment in effect […]
Vero Beach FL, August 10, 2016 – Nascent Biotech, Inc., (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce that through the non-dilutive funding recently received, it has paid nearly $1.7 million in payables and debt, plus created positive shareholders equity. “With this funding we are now able to advance our asset through accelerated […]
Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China. July 18, 2016 10:00 am EDT Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, FL, USA Public Company Information: OTC: NBIO Taizhou, Zhejiang Province, China & Vero Beach, FL USA.- Nascent Biotech, Inc. (OTC: NBIO), and Zhejiang Hisun Pharmaceutical Company Ltd., […]
Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA for its Pritumumab product for the treatment of Pancreatic cancer. According to Industry statistics, there are approximately 49,000 new cases of Pancreatic Cancer […]
Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & Investment Risk at Franklin Templeton Investments, has joined its Board of Directors. Mr. Karas is a Certified Public Accountant and has extensive accounting, auditing, finance and consulting […]
Vero Beach, FL, April 7, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today the addition of Dr. Ralph Zipper, MD, FACOG, FPMRS to its Advisory Board. Dr. Zipper currently is a practicing physician and COO of Biofuse Medical Technologies, Inc. “Dr. Zipper’s vast experience as an innovator in the […]
San Diego, CA September 21, 2015 – Nascent Biotech, Inc. (“Nascent” or “the Company”) (PINK.BB: NBIO), reached an agreement with the licensor whereby the licensor will receive cash payments totalling $63,000 and 200,000 shares of the Company’s common stock plus a 1% royalty of net sales of the Company product up to $1 million in […]
San Diego, CA September 17, 2015 – Nascent Biotech, Inc, (“Nascent” or “the Company”) (PINK.BB: NBIO) is pleased to announce that it has retired the $ 60,000 convertible debenture effective yesterday. The convertible debt could have potentially been converted into 6,000,000 shares of the Company’s common stock, thus diluting all the shareholders by nearly 30%. […]